235 related articles for article (PubMed ID: 12888878)
1. The role of PAR4 in thrombin-induced thromboxane production in human platelets.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Teng CM
Thromb Haemost; 2003 Aug; 90(2):299-308. PubMed ID: 12888878
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
4. YD-3, a novel inhibitor of protease-induced platelet activation.
Wu CC; Huang SW; Hwang TL; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 2000 Jul; 130(6):1289-96. PubMed ID: 10903968
[TBL] [Abstract][Full Text] [Related]
5. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
6. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
[TBL] [Abstract][Full Text] [Related]
7. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
9. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
10. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets.
Henriksen RA; Hanks VK
Arterioscler Thromb Vasc Biol; 2002 May; 22(5):861-6. PubMed ID: 12006403
[TBL] [Abstract][Full Text] [Related]
11. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
[TBL] [Abstract][Full Text] [Related]
12. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
13. Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets.
Wu CC; Wang WY; Wei CK; Teng CM
Thromb Haemost; 2011 Jan; 105(1):88-95. PubMed ID: 21057701
[TBL] [Abstract][Full Text] [Related]
14. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PAR4 signaling mediates ethanol-induced attenuation of platelet function in vitro.
Kasuda S; Sakurai Y; Shima M; Morimura Y; Kudo R; Takeda T; Ishitani A; Yoshioka A; Hatake K
Alcohol Clin Exp Res; 2006 Sep; 30(9):1608-14. PubMed ID: 16930224
[TBL] [Abstract][Full Text] [Related]
16. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
17. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.
Duvernay M; Young S; Gailani D; Schoenecker J; Hamm HE
Mol Pharmacol; 2013 Apr; 83(4):781-92. PubMed ID: 23307185
[TBL] [Abstract][Full Text] [Related]
18. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
19. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
20. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
